Drivers of hospital costs in ANCA-associated vasculitis patients with long-term follow-up—a real-world cost analysis
This real-world cost analysis demonstrates that the burden of infections and comorbidities, both related to CS use, is higher than that of relapses on hospital costs in AAV patients. Thus, this study implicates clinicians considering hospital costs should focus on reducing CS and achieving CS-free remission to prevent infections and comorbidities.
Authors
- Ton J. Rabelink (ORCID: https://orcid.org/0000-0001-6780-5186)
- Wilbert B. van den Hout (ORCID: https://orcid.org/0000-0002-6425-0135)
- Jolijn R. van Leeuwen (ORCID: https://orcid.org/0000-0001-9341-7566)
- Y K Onno Teng (ORCID: https://orcid.org/0000-0001-9920-2195)
- Frouzan H. Soltani
Institutions
- Leiden University Medical Center (NL)
Publication Details
- Journal
- Clinical Kidney Journal
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1093/ckj/sfaf267
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00